4 clinics shown
Dr. Walid A. Jaziri operates a psychiatric practice on New London Turnpike in Norwich, providing outpatient mental health services for adults. The practice focuses on psychiatric evaluations and medication management. Specific procedural treatments such as TMS or esketamine are not detailed in available information; prospective patients should contact the office to confirm current treatment offerings beyond standard psychiatric care.
Psychiatric evaluations and medication management are provided at this Norwich practice on New London Turnpike, where Dr. Kelly Jaziri treats adults with mood disorders, anxiety, and related conditions. The practice operates as an outpatient psychiatry service; specific procedural treatments such as TMS or esketamine are not detailed in available information. Patients seeking those modalities should confirm availability directly with the office during initial contact.
Norwich Psychiatric Center operates as an outpatient psychiatric facility on New London Turnpike in Norwich, Connecticut, providing medication management and psychiatric evaluations. The practice employs psychiatrists, nurse practitioners, social workers, and counselors who treat adults and families with mood disorders, anxiety, and relationship concerns. Specific procedural treatments such as TMS or esketamine are not detailed in available listings; patients should contact the center directly to confirm treatment modalities beyond standard psychiatric care and counseling services.
Southeast Mental Health Authority operates a community mental health center in downtown Norwich, providing psychiatric services and addiction treatment for Connecticut residents. The facility on West Thames Street offers outpatient behavioral health care, including medication management and substance use disorder programs. As a state-affiliated provider, the center accepts Medicaid and serves uninsured individuals through Connecticut's public mental health system. Specific procedural treatments like TMS or esketamine are not listed in available information.
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.